Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 54Recurrence 5Neoplasms, Plasma Cell 3Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 2Renal Insufficiency 1Plasmablastic Lymphoma 1Kidney Failure, Chronic 1Corneal Diseases 1

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × belantamab mafodotin × Clear all
NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Wake Forest University Health Sciences

Phase 1/2 Active not recruiting
70 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04680468 2026-03-23

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

University of Pennsylvania

Phase 2 Active not recruiting
41 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

M.D. Anderson Cancer Center

Phase 1 Recruiting
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡